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The patient was a 28-year-old white female
who was referred to an academic occupa-
tional/environmental medicine center (the
“center”) in April 2000 for evaluation of cad-
mium exposure. She had been working for 3
years as an employee of a metals shop that spe-
cialized in producing materials used in the jew-
elry manufacturing industry. Her speciﬁc job
duties involved taking precious metals (gold,
silver, etc.) and mixing them with a portion of
solid cadmium with a metal stick. She would
then melt the metal–cadmium mixture. Once
it hardened, the patient would blast the alloy
with liquid nitrogen, add brighteners and
other chemicals, and sift the powdered mixture
to produce a gold solder past product. She
described being exposed to the metal mixture
during various stages in the process in solid,
fume, and powdered forms. She wore eye pro-
tection, but was not required to wear nor was
provided with respiratory protection, gloves, or
other garment protection. The patient recalled
that, after work, her nasal passages were fre-
quently coated with brown waxy soot. 
In August of 1999, the patient began to
notice left ﬂank pain and increased frequency
of urination. She was treated for an upper res-
piratory infection but continued to notice per-
sistence in her symptoms. Two months later, a
supervisor visiting from another company
warned her that she was not wearing proper
protective equipment and that, among the
metals she was being exposed to, cadmium and
copper were particularly dangerous. The
patient reported this to her primary physician,
who then ordered blood cadmium and copper
levels. Her blood cadmium and copper levels
were 19.2 µg/L and 1.88 µg/mL, respectively
(normal levels of < 5.0 µg/L and 0.75–1.45
µg/mL, respectively). She alerted her company,
which reassigned her to a position free of direct
work with cadmium. A renal ultrasound in
November 1999 was within normal limits.
Repeat blood cadmium in late November
1999 showed a level of 26 µg/L. Her 24-hr
urinary β2-microglobulin level was 0.16 mg/L
(normal < 0.12 mg/L). Subsequent testing
(Figure 1) showed blood cadmium and urinary
β2-microglobulin levels that ﬂuctuated at high
or high normal levels before declining. 
The patient developed symptoms of short-
ness of breath, chest pain, and anxiety and
resigned from her job in January 2000. Her
physical examination at the center showed a
blood pressure of 124/80 and no remarkable
findings with respect to her cardiovascular,
pulmonary, skin, oral, gastrointestinal, or neu-
rologic systems. A chest X ray and spirometry
were within normal limits. A repeat 24-hr uri-
nary β2-microglobulin level was 0.07 mg/L. 
Case Discussion
This patient, a premenopausal, nonsmoking
female, was clearly exposed occupationally to
cadmium and had evidence of having accu-
mulated a signiﬁcant cadmium body burden
as well as a transient cadmium-related
nephropathy. Over a 3-year period during
which she executed tasks that placed her at
risk for both oral and respiratory exposures to
a number of metals, including cadmium,
without adequate personal protective equip-
ment, the patient performed mixing, a close-
contact manual process that required frequent
handling of powder and paste, as well as melt-
ing and blasting, both temperature-driven,
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A 28-year-old female presented for evaluation of left flank pain and polyuria after having been
exposed to cadmium in the jewelry manufacturing industry for approximately 3 years. This
patient possessed both elevated 24-hr urinary β2-microglobulin and elevated blood cadmium lev-
els. Approximately 6 months after initial presentation, the patient resigned from her job due to
shortness of breath, chest pain, and anxiety. Exposure to cadmium in the jewelry industry is a sig-
niﬁcant source of occupational cadmium exposure. Other occupational sources include the manu-
facture of nickel–cadmium batteries, metal plating, zinc and lead reﬁning, smelting of cadmium
and lead, and production of plastics. Cadmium is also an environmental pollutant that accumu-
lates in leafy vegetables and plants, including tobacco. Major toxicities anticipated from cadmium
exposure involve the renal, pulmonary, and, to a lesser extent, gastrointestinal systems. These
include the development of renal proximal tubular dysfunction, glomerular damage with progres-
sive renal disease, and respiratory symptoms including pneumonitis and emphysema. Low-level
cadmium exposure has also been associated with increased urinary calcium excretion and direct
bone toxicity, effects that recent research suggests may result in the development of osteoporosis.
The body burden of cadmium, over half of which may reside in the kidneys, is most often mea-
sured through the use of urinary cadmium levels. Blood cadmium measurements generally reﬂect
current or recent exposure and are especially useful in cases with a short exposure period and only
minimal accumulation of cadmium in the kidneys. Both β2-microglobulin and α1-microglobulin
serve as organ-speciﬁc, early-effect biomarkers of tubular proteinuria and thus play a role in identi-
fying early signs of cadmium-induced renal damage in those with potential exposures. In addition
to ensuring workplace compliance with Occupational Safety and Health Administration-mandated
monitoring and screening measures, it is prudent for those with cadmium exposure to maintain
adequate intake of both iron and calcium, appropriate measures even in the absence of exposure.
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and other metals. The patient’s own descrip-
tion of brown soot habitually coating her nasal
passages after her shift conveys a sense of the
degree of these exposures.
Occupational sources of cadmium. Previous
cases of cadmium overexposure in the jewelry-
making industry have been reported. Baker et
al. (1979) described cadmium intoxication
secondary to cadmium oxide exposure in jew-
elry brazers and solderers. The symptom pro-
file of those affected matched that of the
patient and included the presence, at a signiﬁ-
cant level, of dysuria (painful or difﬁcult uri-
nation), polyuria (copious and hence frequent
urination), dyspnea (shortness of breath, difﬁ-
cult or labored breathing), chest pain, irri-
tability, fatigue, headache, and dizziness
(Baker et al. 1979).
In general, the use of cadmium in a variety
of industries has steadily climbed over the last
40 years, but actual occupational exposures
have declined markedly over the last 20 years
following the adoption of more stringent
exposure limits in most industrialized nations
(Penney 1993). Nonetheless, it has been esti-
mated that approximately 512,000 workers in
the United States are in environments each
year where a cadmium exposure may occur
(ATSDR 1999). Table 1 provides a summary
of available information on the range of occu-
pations with exposures to cadmium, presented
in relative order of potential exposure, from
highest to lowest.
Environmental sources of cadmium.
Cadmium is a ubiquitous environmental pol-
lutant (Staessen et al. 1999) that has no known
biological function in humans. Cadmium
occurs in nature as a natural component of
rock and sediment, soil and dust, air and
water, and plant and animal tissues (Pinot
2000). Of the estimated 25,000–30,000 tons
of cadmium released into the environment
each year, approximately one-half is liberated
from the weathering of rocks into river and
ocean water. Forest fires and volcanoes also
release some cadmium into the air (ATSDR
1999). Anthropogenic cadmium resulting
from the industrial production of batteries,
plastics, alloys, and synthetic materials is
released into the environment in the form of
atmospheric emissions (70%), liquid efﬂuents,
sludges, and solid waste (Pinot 2000). The
release of cadmium due to human activities is
estimated at 4,000–13,000 tons/year, with
mining and the burning of fossil fuel serving
as the major contributors (ATSDR 1999).
Polluted industrial sites are continuous
sources of environmental cadmium; leaching
of cadmium into groundwater and distribu-
tion of metal-loaded soil particles by lateral
wind erosion are two primary mechanisms
(Staessen et al. 1999).
Cadmium itself tends to accumulate in
leafy vegetables and plants, including tobacco,
that are grown on contaminated soils rather
than in seed or root crops (Pinot 2000). As a
result, even individuals who do not encounter
cadmium in the workplace are at risk of expo-
sure. Levels of such exposures have been ris-
ing, as reflected by a study in France
demonstrating a 10-fold rise in the concentra-
tion of cadmium in human bones during the
20th century (Jaworowski et al. 1985;
Staessen and Lauwerys 1993). In the United
States and Europe, the average uptake via
ingestion in unpolluted areas has been esti-
mated to be from 10–25 µg/day (Pinot
2000). High fiber diets and a diet rich in
shellfish increase the dietary intake substan-
tially, although absorption may not increase
proportionally.
Even though the gastrointestinal absorp-
tion of cadmium is only a few percent, the
absorption of cadmium in the lungs is
10–50%. As a consequence, cigarette smok-
ing is a major route for nonoccupational lung
exposure. One cigarette contains about
1–2 µg of cadmium, roughly 10% of which is
inhaled; based upon a 50% absorption rate, a
person who smokes 20 cigarettes (1 pack) per
day will absorb about 1–3 µg of cadmium.
Smokers, on average, have 4–5 times higher
(~1.5 µg/L) blood cadmium (B-Cd) levels
than nonsmokers. Interestingly, despite the
high cadmium content of cigarette smoke,
there is little evidence for signiﬁcant exposure
from passive smoking (ATSDR 1999; Elinder
et al. 1983; Ikeda et al. 1999).
Biologic testing. Due to the close relation-
ship between the cadmium concentration in
the urine and the kidney, urinary cadmium
(U-Cd) has been used as an estimate of the
body burden of cadmium (Järup et al. 1997).
This is sensible because after long-term expo-
sure, the kidneys may contain more than half
of the body burden of cadmium (Börjesson et
al. 2001). In cases of renal tubular damage,
however, the use of U-Cd for estimating dose
may be problematic, because although the
urinary excretion of cadmium is initially
increased after renal injury, at a later stage,
urinary excretion of cadmium decreases once
overall kidney cadmium burden declines
(Järup et al. 1998b, 2000; Moon et al. 1999).
In currently exposed workers, U-Cd is
considered to be more reflective of the total
body burden than B-Cd (Penney 1993).
Nonetheless, B-Cd levels are generally
regarded as a reflection of current or recent
exposure and are especially useful in cases
with a short exposure period and only mini-
mal accumulation of cadmium in the kidneys
(Järup et al. 1998b; Moon et al. 1999). B-Cd
levels, however, readily fluctuate due to
recent exposures, including smoking (Järup
et al. 1997).
Elevations in B-Cd levels can be measured
within weeks after an acute exposure, as they
were in the case of our patient. If exposure
continues, B-Cd remains relatively stable and
can be used as a time-averaged estimate of
dose; within a few months, the B-Cd reaches a
concentration that corresponds to the inten-
sity of the exposure (Järup et al. 1998b,
2000). Following the cessation of exposure,
the decay of B-Cd can be described by the
sum of two exponential functions. A fast com-
ponent, with an initial half-life of about 2
months (Börjesson et al. 2001), 2–3 months
(Järup et al. 1998b), or 3–4 months (Järup et
al. 1997), reflects recent exposure. A slow
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Figure 1. Biologic exposure measurements for the
patient. 
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Table 1. Industries and job tasks associated with cadmium exposure.
Industry-associated exposure Job task
Nickel–cadmium battery manufacturing Plate-making, impregnation, assembly
Zinc reﬁning/ cadmium smelting Multiple stages of cadmium production
Plastics: cadmium-containing pigment production Crushing, milling, wet system processes
Plastics: dry color formulating Material handling, mixing, grinding, cleaning
Plastics, PVC: cadmium-based stabilizer production Drying, crushing, blending, oxide charging
Metal plating: automotive, electronic, aerospace, marine Mechanical plating or electroplating
(35% of all worldwide cadmium use)
Alloy production with copper, zinc, lead, silver, tin Melting, casting
Lead smelting and reﬁning Material handling, casting, reﬁning, furnace operation
Iron and steel production Welding, furnace/cupola operation, maintenance
Coal-ﬁred electrical utilities, waste incineration Inspection, maintenance, malfunction of boilers/ovens
General industry (occupational history should include  Chemical mixers, electroplaters, furnace operators/
queries on these tasks) molders, kiln/kettle operators, heat-treaters,
equipment cleaners, metal machine operators, 
painters, maintenance workers, mechanics, welders, 
brazers, solderers
Other occupations Jewelry producers, ceramists, artists, theater crafts
Data from Penney (1993).component, with a half-life of several decades,
reflects long-term exposure (Börjesson et al.
2001) and, much like U-Cd, can reflect the
body burden several years after the end of
exposure (Järup et al. 1998a, 2000). This
indicates that both B-Cd and U-Cd are valid
as indicators of long-term environmental
exposure of the general population to cad-
mium. Several studies have supported this
assumption and the close correlation between
B-Cd and U-Cd in such circumstances (Liu
et al. 2001; Moon et al. 1999; Roels et al.
1993). In fact, many years after an exposure,
B-Cd is likely better than U-Cd as an indica-
tor of previous exposure because if tubular
damage has occurred, U-Cd measurements
may be difﬁcult to interpret (Börjesson et al.
2001; Ikeda et al. 1999; Järup et al. 2000).
The distributions of B-Cd and U-Cd values
seen in the general U.S. population are shown
in Tables 2 and 3.
The Occupational Safety and Health
Administration’s (OSHA) revised limits for
workplace biomonitoring of cadmium have
been in operation since 1 January 1999. Based
on blood testing for cadmium and urine mon-
itoring for cadmium and β2-microglobulin,
OSHA has created three levels of exposure
that are described in Table 4. Medical removal
is mandatory for Category C designations,
although with respect to β2-microglobulin,
medical removal is mandatory only when
β2-microglobulin > 750 µg/g creatinine and
either U-Cd > 3 µg Cd/g creatinine or B-Cd >
5 µg/L whole blood. Return to work is per-
missible when Category A biomonitoring cri-
teria have been met and the actions described
in Table 5 have been completed.
Recent studies have indicated that elevated
protein HC (α1-microglobulin) is an earlier
and more sensitive indicator of cadmium-
induced renal damage than β2-microglobulin
(Alfvén et al. 2000; Hunder et al. 2001; Ikeda
et al. 1999; Järup and Elinder 1993; Järup et
al. 2000). Given its stability in the low pH of
urine, in contrast to β2-microglobulin, protein
HC appears to be a more practical marker of
renal tubular damage. Within the past decade,
investigators (Järup et al. 2000; Jaworowski et
al. 1985; Staessen et al. 1999) have found simi-
lar protein HC reference values (95% cutoff
points) for determining the presence of tubular
proteinuria, namely 0.6 mg protein HC/mmol
creatinine for women and 0.8 mg protein
HC/mmol creatinine for men. Currently,
however, there are no ﬁrmly established pro-
tein HC reference cutoff values for tubular
dysfunction, and as such, despite the promise
seen with protein HC use, a β2-microglobulin
level > 300 µg/g creatinine will continue to
maintain its acceptance as a reliable indicator
of functional damage to the proximal
convoluted tubules in the kidneys (Järup et al.
2000; Moon et al. 1999). 
Our patient possessed a significant body
burden of cadmium. Her peak B-Cd mea-
surement was 26 µg/L, considerably above
the OSHA Category C limit of 10 µg/L and
signiﬁcantly above the cadmium levels in the
general population. This B-Cd level man-
dated medical removal until biomonitoring
revealed that Category A criteria were fulﬁlled
(Table 4).
Renal effects. The patient’s urinary level
of β2-microglobulin also exceeded reference
values. This elevation in β2-microglobulin
provides evidence that she had developed a
proximal tubule defect, it increases her likeli-
hood for maintaining an element of renal
tubular dysfunction, and depending on the
degree and chronicity of her exposure, it also
increases her risk for developing glomerular
damage and progressive renal disease.
In total, approximately one-third of the
cadmium absorbed in the body is stored in
the kidneys, where it persists with a biologic
half-life of approximately 10–30 years.
Immediately after gastrointestinal or pul-
monary absorption, cadmium circulates in
the blood mainly bound to albumin and
other high molecular weight proteins. These
complexes are largely absorbed in the liver,
and the uptake of cadmium by the kidney is
limited. In chronic exposure or in situations
long after a single exposure, however, much
of the plasma cadmium is bound to metal-
lothionein (MT). Due to its small molecular
size, cadmium–MT, in contrast to the cad-
mium–albumin complex, is efﬁciently ﬁltered
through the glomerular membrane and reab-
sorbed by renal tubular cells through pinocy-
tosis. The cadmium–MT complex is then
metabolized within lysosomes and cadmium
ion is released (Järup et al. 1998b).
Cadmium-induced renal injury initially
presents as tubular proteinuria that can be
quantified through the measurement of the
urinary excretion of low molecular weight pro-
teins such as β2-microglobulin, retinol binding
protein and protein HC and enzymes such as
N-acetyl-β-glucosaminidase. With continued
cadmium exposure, this tubular dysfunction
progresses, and ultimately glomerular damage
characterized by a decreased glomerular ﬁltra-
tion rate may emerge (Elinder et al. 1983;
Pinot 2000). Several studies have documented
that in almost all cases, this cadmium-induced
tubular proteinuria and damage is irreversible
even if exposure ends (Järup et al. 1998a,
1998b, 2000; Järup and Elinder 1993). In a
recent study detailing a 5-year follow-up of a
subpopulation chosen for its high urinary cad-
mium levels, Hotz et al. (1999) concluded
that in environmentally exposed populations,
tubular effects were not associated with pro-
gressive deterioration in renal function after
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Table 2. Selected percentiles of blood cadmium concentrations (µg/L) for the U.S. population.
Sample Percentile (95% conﬁdence interval)
size 10th 25th 50th 75th 90th
Total, ≥ 1 of age 3,189 < LODa  < LOD 0.3 0.5 0.9
(0.2–0.3) (0.4–0.6) (0.7–1.1)
Sex
Male 1,594 < LOD < LOD < LOD 0.5 0.9
(0.4–0.6) (0.8–1.1)
Female 1,595 < LOD < LOD 0.3 0.5 0.9
(0.2–0.3) (0.4–0.6) (0.7–1.2)
Race/ethnicity
Black, non-Hispanic 693 < LOD < LOD < LOD 0.5 0.9
(0.4–0.6) (0.7–1.2)
Mexican American 1,289 < LOD < LOD 0.3 0.5 0.7
(0.2–0.4) (0.4–0.5) (0.6–1.0)
White, non-Hispanicb 1,207 < LOD < LOD 0.3 0.5 0.9
(0.2–0.3) (0.4–0.6) (0.7–1.1)
Age group
1–19 years 1,541 < LOD < LOD < LOD < LOD 0.4
(0.3–1.0)
≥ 20 years 1,648 < LOD < LOD 0.3 0.6 1.0
(0.3–0.4) (0.5–0.7) (0.8–1.3)
LOD, limit of detection. Data from the National Health and Nutrition Examination Survey (CDC 1999). 
aLOD = 0.3 µg/L blood. bIncludes other race/ethnic groups. 
Table 3. Selected percentiles of urine concentrations and creatinine-adjusted levels of cadmium in the
U.S. population ≥ 6 years of age.
Sample GM Percentile (95% conﬁdence interval)
size (95% CI) 10th 25th 50th 75th 90th
U-Cd (µg/L of urine) 1,007 0.32 0.10 0.18 0.33 0.57 0.95
(0.30–0.33) (0.08–0.12) (0.15–0.19) (0.29–0.35) (0.52–0.62) (0.85–1.04)
Cadmium (µg/g of creatinine) 1,007 0.29 0.11 0.17 0.27 0.46 0.74
(0.27–0.31) (0.10–0.13) (0.15–0.19) (0.26–0.30) (0.43–0.50) (0.66–0.79)
GM, geometric mean. Data from the National Health and Nutrition Examination Survey (CDC 1999).the implementation of exposure reduction
measures. In the case of ongoing low-level
environmental exposure, however, cadmium
does appear to be a determinant for the devel-
opment of end-stage renal disease (Hellström
et al. 2001).
During the past decade, several studies
have shown that urinary cadmium concentra-
tions of 2–4 nmol/mmol creatinine are asso-
ciated with tubular proteinuria in both
occupationally and environmentally exposed
populations (Järup et al. 2000). A meta-
analysis of data from these and other studies
indicated that a urinary cadmium level of
2.5 µg/g creatinine is associated with a 4%
excess prevalence of renal tubular damage.
Based on these results, it can be estimated
that in order to prevent tubular damage that
can progress to clinical disease, cadmium lev-
els should be kept < 2.5 µg/g creatinine in the
urine and < 50 mg/kg in the kidney cortex
(Järup et al. 1998b).
Over the long term this tubular damage
can also affect the excretion of calcium. In
workers occupationally exposed to cadmium,
an increased prevalence of kidney stones has
been documented and likely relates to the
increased urinary excretion of calcium (Elinder
et al. 1985; Ikeda et al. 1999; Järup et al.
1998a). One review noted a lifetime preva-
lence rate of 18–44% in those with occupa-
tional cadmium exposure compared to a rate
< 5% in control populations (Borak 1992;
OSHA 1993).
Respiratory effects. Other manifestations
of cadmium toxicity that were not apparent in
the patient include those characteristic of both
acute and chronic exposure. Metal fume fever
is most commonly described in workers
exposed to metal oxide fumes during welding
or soldering zinc- or cadmium-containing
metals. Symptoms, which appear within 3–10
hr after exposure, initially include throat irrita-
tion with an associated metallic taste, followed
within hours by a nonproductive persistent
cough, fever, chills, malaise, and myalgias in
the back and limbs. Nausea, vomiting, and
headache may occasionally complete the symp-
tom proﬁle. These signs and symptoms peak
roughly 18 hr postexposure and normally
resolve completely within a few days (Balmes
and Scannell 1997; OSHA 1993).
Higher dose cadmium fume inhalation
may lead to a more advanced and prolonged
pulmonary response ranging from tracheo-
bronchitis to pneumonitis to pulmonary
edema. Initial symptoms may mimic metal
fume fever, but these then progress within
hours to days to include severe dyspnea with
wheezing, cyanosis, tachycardia, pleuritic
chest pain, abdominal pain, diarrhea, hemop-
tysis, and life-threatening noncardiogenic
pulmonary edema. Even a few hours of expo-
sure to 2–3 mg/m3 can have fatal results, and
those who survive may have impaired lung
function years after a single episode.
Respiratory effects may also occur as a result
of high exposures to cadmium dust, but these
are usually less severe than those caused by
cadmium fumes (ATSDR 1999; Hotz et al.
1999; OSHA 1993). 
A number of morbidity studies have docu-
mented that longer-term inhalation exposure
to levels of cadmium below that which causes
acute disease can lead to shortness of breath,
obstructive patterns of lung function with
decreases in forced vital capacity, bronchitis,
and emphysema. Survivors of cadmium-
related pneumonitis appear to be particularly
vulnerable, and there is evidence that cad-
mium may accelerate the development of
emphysema in smokers (Penney 1993). In
both humans and animals, mild to moderate
pulmonary ﬁbrosis has been documented with
chronic inhalation exposure to cadmium
oxide and cadmium sulﬁde (ATSDR 1999).
Gastrointestinal effects. Cadmium inges-
tion can also be associated with severe nausea,
persistent vomiting, salivation with choking,
abdominal cramps, diarrhea, vertigo, and loss
of consciousness. This symptom profile has
been mainly observed in those acutely
exposed to high levels of cadmium in food or
beverages. Gastrointestinal sequelae may also
result from mucous membrane deposition
and subsequent ingestion of large cadmium
dust particles. Smoking in a cadmium-conta-
minated workplace may also increase expo-
sure through the oral route (ATSDR 1999;
Hotz et al. 1999; OSHA 1993).
Skeletal effects. Exposure to cadmium can
have both indirect and direct effects on bone
loss. Cadmium-induced bone damage may be
mediated through the dysfunction of renal
tubular cells caused by increased cadmium
concentration in the kidneys. Within the
renal tubular cells, cadmium reduces the nor-
mal activation of vitamin D3 to the hormone
1,25-dihydroxy-calcitriol; this in turn
impedes calcium absorption from the duode-
num and active reabsorption of calcium in
the distal convoluted tubule (Järup et al.
1998b; Staessen and Lauwerys 1993).
Cadmium-induced tubular dysfunction also
leads to urinary losses of calcium and phos-
phate and subsequent decreases in serum cal-
cium. Increased secretion of parathyroid
hormone then may lead to calcium and phos-
phate mobilization from bone, impaired bone
mineralization, and hence osteoporosis and
osteomalacia (Berglund et al. 2000).
There is also increasing evidence that cad-
mium acts directly on bone tissue. In the past,
experimental data indicated that cadmium
could affect bone mineralization without clear
signs of renal effects (Berglund et al. 2000;
Pinot 2000). Now it is more ﬁrmly established
that cadmium exposure at levels that have not
impaired renal function can target bone
directly, causing early bone loss by decreasing
bone formation and increasing bone resorption
(Wilson and Bhattacharyya 1997). Direct
effects on osteoblast and osteoclast function
have been shown in vitro and experimentally
in mice (Berglund et al. 2000). In vitro, cad-
mium decreases osteoblastic accumulation of
calcium and induces the release of 45Ca from
prelabeled cultured limb bones (Wilson and
Bhattacharyya 1997). Cadmium might further
interact with bone cells by directly diminishing
their ability to mineralize and by inhibiting
procollagen C-proteinases and collagen pro-
duction (Hunder et al. 2001; Staessen and
Lauwerys 1993). In vivo, cadmium increases or
accelerates osteoclast-induced bone resorption
(Wilson and Bhattacharyya 1997). Further
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Table 4. OSHA exposure classiﬁcation for biologic monitoring of cadmium.
U-Cd Urinary β2-microglobulin B-Cd
Category (µg/g creatinine) (µg/g creatinine) (µg/L)
A ≤ 3 ≤ 300 ≤ 5
B3  < U-Cd ≤ 7 300 < β2-microglobulin ≤ 750 5 < B-Cd ≤ 10
C>  7 >  750 > 10
Data from OSHA (1993). 
Table 5. OSHA-mandated action based on biomonitoring category.
Action Category A Category B Category C
Biomonitoring Annually Semiannually Quarterly
Medical exam including PFTs, CXR,  Biennially Annually Semiannually
BUN, creatinine, CBC, U/A
Time frame of medical exam Within 90 days of receiving biomonitoring results
Assess within 2 weeks and correct  Source of cadmium exposure, work practices, personal
within 30 days hygiene and hygiene facilities, respirator usage, smoking
history, engineering controls
Reassessment Periodically at 
intervals ≤ 6 months
Medical removal Discretionary Discretionary Mandatorya
Abbreviations: BUN, blood urea nitrogen; CBC, complete blood count; CXR, chest X-ray; PFT, pulmonary function test;
U/A, uric acid. Data from OSHA (1993).
aMedical removal for category C is mandatory except when both U-Cd and B-Cd are classiﬁed as exposure category A.analysis also revealed that the effect of cad-
mium on bone might be greatest at the onset
of cadmium exposure; as such, intermittent
exposures may be required to potentiate a
bone effect (Wilson and Bhattacharyya 1997). 
It has been well documented among the
general population that the urinary excretion
of cadmium is positively associated with the
urinary excretion of calcium (Bæcklund et al.
1999). In the CadmiBel study, Staessen and
colleagues (Staessen et al. 1991a, 1991b,
1993, 1999) showed that after adjustment for
confounders, doubling of the urinary cad-
mium excretion was associated with a
0.25-mmol rise per day in urinary calcium
excretion. Similarly, in their cohort of
Swedish women, Järup et al (1998b) recently
documented a 90% increase in urinary cal-
cium excretion among those whose urinary
cadmium concentration was > 1 nmol/mmol
creatinine (Staessen and Lauwerys 1993).
In people exposed to low levels of cad-
mium, urinary calcium excretion thus appears
to serve as a biomarker for tubular dysfunction.
Aoshima and Kasuya (1991) and Tsuritani et
al. (1992) have reported increased urinary
β2-microglobulin, increased serum creatinine,
and decreased plasma calcitriol in those with
cadmium-induced renal damage (Järup et al.
1998b; Wilson and Bhattacharyya 1997). Most
recently, Wu et al. (2001) described a signiﬁ-
cant and linear dose–response relationship
between the prevalence of hypercalciuria and
U-Cd excretion, most notably at U-Cd levels
>2   µg/g creatinine. With respect to the clini-
cal relevance of these ﬁndings, in a prospective
population study, Staessen et al. (1999) docu-
mented that a 2-fold increase in cadmium
excretion at baseline correlated with a 73%
increased risk of fractures in women and with
a 60% increased risk of height loss in men
(measured as height loss that exceeded the
90th percentile). Similarly, Alfvén et al.
(2000) showed that both increased urinary
cadmium excretion and renal tubular dysfunc-
tion were associated with signs of osteoporo-
sis, as measured by bone mineral density, in
men and older women.
Other effects. Cadmium has been classiﬁed
as a human carcinogen (group I) by the
International Agency for the Research on
Cancer on the basis of both human and experi-
mental animal data. Several studies of cad-
mium-exposed workers have shown a small
but statistically signiﬁcant increase in lung can-
cer, although controversy exists over the degree
of excess mortality attributable to the con-
founding exposures of arsenic or nickel.
Cadmium is also suspected to cause prostate
cancer in humans, although follow-up studies
have been unable to confirm this suspicion
(Järup et al. 1998b; OSHA 1993; Tencer et al.
1996; Waalkes 2000). Cadmium exposure has
been linked with olfactory impairment, most
notably in those with proteinuria (Penney
1993). Yellowing of the teeth and microcytic
hypochromic anemia have been described as
well (Hu 2001). Most studies of workers occu-
pationally exposed to cadmium, however, have
not found cadmium-related cardiovascular
toxicity (ATSDR 1999; Shimbo et al. 2000).
Modiﬁers of cadmium absorption. Studies
in Sweden have shown that 10–67% of pre-
menopausal women have low (Berglund et al.
1994) or empty iron stores (Bæcklund et al.
1999) and have identiﬁed this as a risk factor
for elevated B-Cd levels in those who are
either environmentally or occupationally
exposed. This is most true among smokers
with low iron stores (Bæcklund et al. 1999;
Ikeda et al. 1999). Berglund et al. (1994)
examined nonsmoking, premenopausal,
nonoccupationally exposed women and found
that low serum ferritin was correlated with ele-
vated B-Cd in this population as well. Animal
studies have supported this ﬁnding, indicating
that gastrointestinal absorption of cadmium is
increased in the setting of low dietary iron,
zinc, and calcium (Berglund et al. 1994).
In clinical situations where concerns exist
regarding either environmental or occupa-
tional cadmium exposure, it would appear to
be clinically responsible to ensure adequacy of
the patient’s iron status, an accepted interven-
tion even in the absence of cadmium expo-
sure. In the case of an ongoing exposure then,
dietary supplementation with iron should be
implemented to theoretically diminish the
degree of cadmium absorption from the
intestinal tract. Similarly, healthcare providers
should counsel their patients to reduce or
eliminate alcohol intake during periods of
cadmium exposure because observations also
indicate that even short periods of ethanol
consumption can increase cadmium absorp-
tion from the gastrointestinal tract. This con-
clusion is further supported by animal data
documenting increased blood and tissue cad-
mium concentrations in rats exposed to both
cadmium and ethanol in comparison with
cadmium alone (Brzóska et al. 2000).
Summary and Conclusion
The patient, a 28-year-old nonsmoker with a
3-year history of occupational cadmium expo-
sure, had evidence of a significant cadmium
body burden and a transient cadmium-related
nephropathy. She met criteria for mandatory
medical removal with a B-Cd level > 10 µg/L;
she was subsequently monitored regularly
until her B-Cd levels approached 1 µg/L. In
the absence of ongoing occupational or envi-
ronmental cadmium exposure, it is likely that
the patient’s risk for progressive renal damage
is slight; nonetheless, the degree of diminish-
ment of her functional renal reserve is
unknown and hence her ability to withstand
further renal damage is uncertain.
In the care of patients similar to this one,
physicians should follow OSHA guidelines
with respect to workplace removal and bio-
logic monitoring. Measurement of urinary
protein HC may also serve as a viable and sen-
sitive marker of cadmium-induced renal dam-
age. Subsequent medical follow-up to evaluate
for the persistence of renal dysfunction is
essential. The healthcare provider should
encourage smoking cessation, and pharmaco-
logic intervention may be considered to aid in
this process. Measurement of iron stores and
continued replacement to ensure their ade-
quacy is recommended, and long-term cal-
cium supplementation with ample hydration
is sensible. From a public health standpoint,
workplace investigation for companion cases
and subsequent workplace and work process
modification is imperative to minimize the
magnitude of future cadmium exposures.
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